Scientists test Long-Term ALS drug to slow devastating decline
NCT ID NCT00424463
Summary
This study tested whether long-term, repeated treatment with the drug edaravone (MCI-186) could help control the progression of ALS, a severe nerve disease. It involved 181 patients who had already completed a prior 24-week trial. Researchers measured changes in patients' ability to perform daily activities and monitored safety over an extended period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Hospital Organization Miyagi National Hospital
Watari-gun, Miyagi, Japan
Conditions
Explore the condition pages connected to this study.